.jetcityimage/iStock Content using Getty Images Morgan Stanley has chosen Eli Lilly (NYSE: LLY) as its own top biopharma selection for 2025 and rated yet another 9 labels in the area as overweight. The financial investment banking company stated in a note that it continues to strongly believe “diabesity is set to end up being.